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http://dx.doi.org/10.1016/j.jds.2013.0Abstract Background/purpose: It is still controversial whether tacrolimus can induce
gingival overgrowth. Calcium channel blockers of nifedipine are commonly used for lessening
the side effect of high blood pressure induced by tacrolimus; however, nifedipine can also
induce gingival overgrowth. This study was conducted to evaluate the effect of concomitant
administration of nifedipine and tacrolimus on gingival overgrowth in rats.
Materials and methods: Thirty-six Sprague-Dawley rats were assigned into four groups,
including a control group. In drug groups, either tacrolimus (1.5 mg/kg) or nifedipine
(30 mg/kg), or both drugs together were administrated daily for 6 weeks. The gingival
morphology was examined macroscopically on the mandibular central papilla from cast models
biweekly, and analyzed by measuring the sulcular probing depth and the keratinized gingival
width around the first mandibular molars immediately after sacrificing. By histology, changes
of papillae, including the connective tissue, and the epithelial and total tissue areas, weret of Periodontology, School of Dentistry, National Defense Medical Center and Tri-Service General
aiwan, ROC.
gh.edu.tw (E. Fu).
iation for Dental Sciences of the Republic of China. Published by Elsevier Taiwan LLC. All rights reserved.
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Results: Significant increases in papillary dimensions, including depth, width, and height, were
observed across all groups after Week 1, with the control group showing less changes than
experimental drug groups. Among drug groups, significantly increased papillary dimensions
were noted in the nifedipine group when compared with groups treated with tacrolimus and
both drugs. Changes in keratinized gingival width were found to be similar in the tacrolimus
and combined-drug groups but greater in the nifedipine group. For probing depth, experi-
mental groups showed greater changes than the control group, but no difference was observed
among the experimental groups. Similar trends were presented for the total and connective
tissue areas; however, the epithelial tissue areas did not show any difference among the four
treatment groups.
Conclusion: Gingival overgrowth could be induced either by nifedipine or by tacrolimus,
although the extent of gingival overgrowth induced by tacrolimus would be less than that by
nifedipine. However, a concomitant administration of nifedipine and tacrolimus did not aggra-
vate the induced gingival overgrowth.
Copyright ª 2013, Association for Dental Sciences of the Republic of China. Published by Else-
vier Taiwan LLC. All rights reserved.Introduction
Gingival overgrowth is one of the adverse effects induced
by various groups of drugs, including cyclosporin A,
nifedipine, and phenytoin. Tacrolimus (FK506) is an
immunosuppressant that was first isolated from Strepto-
myces tsukubaensis in 1984. Tacrolimus has been used
successfully as an alternative to cyclosporin A for pre-
venting graft rejection and treating autoimmune dis-
eases.1 It shares similar pharmacodynamics to cyclosporin
A, but has nephrotoxicity, neurotoxicity, and disturbances
in glucose metabolism. By contrast, tacrolimus has ad-
vantages over cyclosporin A; unlike cyclosporin A, tacro-
limus does not cause hyperlipidemia, hypertension, and
hirsutism.1 Many clinical researches have demonstrated
the benefit of tacrolimus in terms of reduced gingival
overgrowth,2e5 and recommended the use of tacrolimus
over cyclosporin A to lower the risk of developing gingival
overgrowth.4e8
To attenuate side effects such as nephrotoxicity and
hypertension, it is a common practice to administer
nifedipine, which may also induce gingival overgrowth,9
along with tacrolimus.10 Several clinical studies have
evaluated the development of gingival overgrowth after
concomitant administration of nifedipine and tacroli-
mus2,4,5,8,11,12 and postulated a synergistic relationship
between calcium channel blockers and tacrolimus in
producing gingival overgrowth.4,5 Despite former at-
tempts to prove the existence of such a relationship, the
effects of coadministration of nifedipine and tacrolimus
on gingival overgrowth remain elusive due to the lack of
an organized experimental design and randomized control
trials. Most previous studies were based on single case
reports or case-series reports without an appropriate
control variable of each treatment drug. Therefore, the
present study aims to evaluate the hypothesis that
concomitant treatment of nifedipine and tacrolimus can
aggravate gingival overgrowth in an animal model through
an experimental design using different drug combinations
as variables.Materials and methods
Experimental design
Thirty-six male Sprague-Dawley rats, 5-week old and
weighing 150e200 g, were assigned randomly into four
groups treated with different drug combinations: control,
tacrolimus, nifedipine, and combined drug (tacrolimus þ
nifedipine) groups. Animals in the tacrolimus group received
tacrolimus dissolved in mineral oil at a daily dose of 1.5 mg/
kgbodyweight via gastric feeding,whereas the control group
received the mineral oil solvent alone. Animals in the nife-
dipinegroup received a daily dose of nifedipine of 30 mg/kg
body weight (Sigma, St Louis, MO, USA) dissolved in dimethyl
sulfoxide (Sigma-Aldrich, St Louis, MO, USA), whereas those
in the tacrolimus þ nifedipine group received both tacroli-
mus andnifedipine, asmentioned above. All the drugs and oil
solvent were delivered daily for 6 weeks. The protocol was
approved by the Institutional Animal Care Committee of the
National DefenseMedical Center, Taipei, Taiwan, prior to the
commencement of this study.Macroscopic evaluation of gingival morphology
From the cast models obtained from dental impressions
(Colte`ne/Whaledent, Altsta¨tten, Switzerland), morpholog-
ical changes of the central mandibular papilla, including
the mesiodistal width, buccolingual depth, and vertical
height, were measured and evaluated biweekly (Fig. 1A), as
described previously.13 In addition, depths of the gingival
sulci at the distobuccal sites of the maxillary and first
mandibular molars were recorded using a stereomicroscope
(Olympus-SZH, Olympus, Tokyo, Japan) via the insertion of
a specially designed plastic gingival probe after sacrificing
the animals by carbon dioxide inhalation at the end of the
experiment.14 Widths of keratinized gingiva at the mesio-,
mid-, and distobuccal sites of the right and left first
mandibular molars were also measured directly using the
methods modified in our previous study.15
Figure 1 Macro- and microscopic analysis for morphological changes in the gingivae examined in this study. (A) Macroscopic
analysis: Photograph I presents the lingual appearance of central mandibular papilla on a stone model. The papillary dimensions,
including the mesiodistal width and vertical height, are measured. Photograph II shows the depth of probing after inserting a plastic
probe into the gingival sulcus at the distobuccal site of the left mandibular first molar. Photograph III indicates the three widths of
keratinized gingiva measured at the mesio-, mid-, and distobuccal sites of the right first mandibular molar (three lines indicate the
widths). (B) Microscopic analysis: histograms present the two tissue levels (levels 1 and 2) of the mandibular central papilla. On the
tissue sections, the central interdental papillae and adjacent roots can be observed clearly. At the transverse plane section of level
1, the junctional epithelia are observed, whereas the most coronal level of alveolar bone crests are noted at the section of level 2.
(The arrows indicate the epithelia, whereas the arrowheads point to the alveolar bone crests; original magnification 20.)
30 S.-Y. Chen et alMicroscopic evaluation of gingival morphology
In this study, gingival tissue specimens (including teeth,
gingiva, and surrounding soft and hard tissues) around the
mandibular incisors were selected for the histological
evaluation of gingival morphological changes. After fixation
in 10% formalin and decalcification with 5% HCl, the spec-
imens were sectioned serially at 6 mm intervals starting
from the base of the central incisal papilla. The routine
hematoxylin and eosin stain method was used for micro-
scopic examination. As modified from our previous study,
two tissue levels were selected for histometric analysis
based on the characteristics of the lingual gingiva between
the roots.16 Briefly, the junctional epithelia and the crest of
the dental alveoli were used as landmarks for tissue levels 1
and 2 (Fig. 1B), respectively. At these two levels, tissue
dimensions, including the tissue mesiodistal width and tis-
sue buccolingual thickness, as well as the connective tis-
sue, epithelial tissue, and total tissue areas were
measured. In this study, five consecutive sections at each
level were selected for histometric measurements.
Statistical analysis
A one- or two-way analysis of variance (ANOVA) was used to
evaluate the differences of the morphological and tissuedimensions of the mandibular central papilla between
different treatment groups and between different intervals.
A repeated measures ANOVA along with the Duncan post hoc
analysis were used to evaluate whether any dependent var-
iables (probing depth or keratinized gingival width) were
correlated with the intersubject factor (drug treatments)
and the intrasubject factor(s) (e.g., the right and left sides
examined and the upper and lower jaws evaluated). The
Duncan post hoc test was further used if any significance was
noted. Significance was set at P < 0.05.
Results
Themandibular central papillae appeared to be larger in the
animals receiving nifedipine and/or tacrolimus when
compared with those in the control rats receiving no drug
[Fig. 2A (IeIV)]. The papillary morphology, measured from
the stonemodels,was summarized (Fig. 2BeE). Thepapillary
buccolingual thickness increased significantly from Week
0 to Week 6, under the influence of the drug delivered
(Fig. 2B and E). The papillary buccolingual thickness was
found to be significantly greater in animal groups treated
with drug/s than in the control group. Among the drug
groups, the greatest thickness was found in the nifedipine
group, whereas the thickness in the tacrolimus and the
tacrolimus þ nifedipine groups was similar (Fig. 2B and E).
Figure 2 Gingival morphology of mandibular central papillae in the four animal groups depending on Tcr and NIF treatment. (A)
Photographs show the lingual aspect of central mandibular papillae and surrounding gingivae of a rat from the control group (I), NIF
group (II), Tcr group (III), and combined drug group (IV) at the end of Week 6 (original magnification 15). (BeD) Plots show gingival
morphological changes of the central mandibular papillae recorded on stone models in four animal groups during 6 weeks
(mean  standard deviations, the buccolingual depth, mesiodistal width, and vertical height). (E) Plot represents the statistical
analyses of plots of BeD. Bars represent means and standard deviations. * Significant difference among the observation intervals or
the treatment groups using two-way ANOVA, whereas the subsets i to iv or a to c were obtained after post hoc analysis if a sig-
nificant difference was achieved (P < 0.001). Cont Z control group; NIF Z nifedipine group; Tcr Z tacrolimus group;
Comb Z tacrolimus þ nifedipine group; BL Z buccolingual; MD Z mesiodistal; VH Z vertical height.
Nifedipine/tacrolimus on gingival overgrowth 31Similar trends were observed in cases of the mesiodistal
width (Fig. 2C and E) and vertical height (Fig. 2D and E).
Results of analyses of the probing depth and keratinized
gingival width around the molars are summarized in Fig. 3.
Significantly greater probing depths were observed in all
three drug groups than in the control group, although no
difference in depth was found between the right and left
sides, as well as between the upper and lower jaws
(Fig. 3A). The keratinized gingival widths were significantly
different between the treatment groups but not betweenthe right and left sides, regardless of whether the widths
were measured at mesio-, mid-, or distobuccal sites
(Fig. 3B). Among the four treatment groups, the greatest
keratinized gingival width was recorded in the nifedipine
group, and no statistical difference was found between the
tacrolimus and the tacrolimus þ nifedipine groups; how-
ever, the keratinized gingival widths in all the three drug
groups were greater than that in the control group.
The histological presentation of the papillae for the four
animal groups is summarized in Fig. 4. Again, the total
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32 S.-Y. Chen et altissue areas were significantly different among the four
treatment groups, regardless of tissue levels. At each tissue
level, significantly greater tissue areas were found in all
drug groups when compared to the control group, with the
greatest area being found in the nifedipine group. Similar
trends were observed in the connective tissue areas, at
each tissue level (except at level 2 tissue area between the
tacrolimus þ nifedipine and the nifedipine groups, where
no statistical difference was found); however, the epithe-
lial tissue areas did not show any difference among the four
treatment groups at both tissue levels (Fig. 4).C T area
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Figure 4 Tissue areas of the central mandibular papilla in the
four animal groups depending on Tcr and NIF treatment. Histo-
grams present the CT and Epi. areas, as well as the total tissue
area, on the histological sections selected at papillary levels 1
and 2. Bars indicate means and standard deviations. * Significant
difference among the animal groups examined at each tissue
level using one-way analyses of variance, whereas the subsets of
AeC were obtained after post hoc analysis if a significant dif-
ference was achieved; significance was set at P < 0.001.
Comb Z tacrolimus þ nifedipine group; Cont Z control group;
CT Z connective tissue; Epi. Z epithelial; NIF Z nifedipine
group; Tcr Z tacrolimus group.Discussion
Whether the concomitant intake of nifedipine can aggra-
vate the morphological changes of gingival during the
administration of tacrolimus was evaluated in vivo in this
study. However, whether tacrolimus induces gingival over-
growth is still inconclusive. Some published human studies
suggest that tacrolimus does not induce gingival over-
growth,2,11 whereas others disapprove this hypothesis or
suggest that the severity of gingival overgrowth is less than
that observed during cyclosporin A administration.4,5,17,18
The confusion in defining this phenomenon may possibly
make the assessment of three-dimensional changes of
gingival morphology in a quantitative manner difficult and
result in the absence of a standardized way to record
gingival overgrowth. In human studies, several methods
have been used to measure the overgrown gingival.19e21
Moreover, gingival overgrowth is not evenly distributed
around the tooth, as gingival overgrowth occurs more
frequently and/or severe on the labial than on the lingual
side and around the anterior than around the posterior
Nifedipine/tacrolimus on gingival overgrowth 33teeth. Similar difficulties appear in animal studies; hence,
this study adopted varied measurements to record gingival
overgrowth macroscopically (including the three-
dimensional stone model, two-dimensional tissue section,
and one-dimensional probing depth and keratinized gingival
width) at different locations of gingivae. A time-dependentTable 1 Development of gingival overgrowth in patients recei
human reports since 1991.
Author (year) Concomitant drug
No. of
patients
Se
(%
1. Adams and
Famili (1991)31
Tcr alone Z 7a
Tcr þ NIF Z 1
0
1
2. James
et al (2001)2
Tcr Z 17
Tcr þ CCB Z 8
Control Z 26
0
2
0
3. Ellis
et al (2004)4
Tcr Z 22
Tcr þ CCB Z 18
CsA Z 100
CsA þ CCB Z 97
8.
21
d
d
4. Spolidorio
et al (2006)11
Tcr Z 61
Tcr þ CCB Z 6
CsA Z 24
CsA þ CCB Z 64
5. de Oliveira
Costa
et al (2006)5
Tcr Z 77
Tcr þ CCB Z 57
CsA Z 194
CsA þ CCB Z 257
9.
24
23
31
6. Greenberg
et al (2008)12
Tcr Z 39
Tcr þ CCB Z 15
CsA Z 28
CsA þ CCB Z 21
Other immunosuppressant Z 8
Others þ CCB Z 1
7. Shiboski
et al (2009)8
Tcr Z 63
Tcr þ CCB Z 22
CsA Z 30
CsA þ CCB Z 5
Others Z 11
Other drugs þ CCB Z 2
8. Cota
et al (2010)32
Tcr Z 31
Tcr þ CCB Z 14
CsA Z 22
CsA þ CCB Z 23
Other Z 35
Other þ CCB Z 10
CDZ concomitant drug; CCBZ calcium channel blockers; CsAZ cycl
GO (þ) Z presence of gingival overgrowth; GO() Z absence
þ/CCB Z with and without CCB.
Bold and underlined values indicate summary of eight clinical human
without CCB.
a The number of patients examined.
b The GO score.19
c The number of patients whose GO score is 30, classified as clinic
d GO was diagnosed as positive when the probing depth 4 mm (Wo
e GE index (Aas, 1963).36increase of gingival dimension in the mandibular central
papillae was observed in all animal groups (Fig. 2E), which
may in part be due to the natural growth of the animals.13
Although our results showed general increases in all di-
mensions over the 6 weeks, a significantly increased
gingival overgrowth was seen consistently in the animalsving Tcr with and without CCB: a summary of eight clinical
GO Suggestion and conclusion
verity
)
Prevalence
Tcr-GO requires
additional evidence
Tcr has no adverse
effects on gingival tissue
Tcr has potential
as an alternative
immunosuppressant
18b
.3
Tcr with/without
CCB: 15% Z 6c/40a
CsA with/without
CCB: 30% Z 59/197
CCB and previously used CsA
are significant risk factors
for Tcr-GO
0% Z 0d/61a
100% Z 6/6
58.3% Z 14/24
84.3% Z 54/64
CCB increased GO number
96b
.86
.5
.4
10.4% Z 8c/77a
28.0% Z 16/57
34.5% Z 67/194
44.7% Z 115/257
Prevalence and severity of
Tcr-GO is lower than that
of CsA-GO; CCB reinforces
the possible synergistic
effect of Tcr-GO
15% Z 6e/39a
27% Z 4/15
36% Z 10/28
76% Z16/21
13% Z 1/8
100% Z 1/1
Tcr is not associated
with GE e
CCB should be avoided by
patients taking CsA and
with poor oral hygiene
13% Z 8e/63a
23% Z 5/22
50% Z 15/30
60% Z 3/5
18% Z 2/11
50% Z 1/2
Tcr is not associated
with GE e
12.9% Z 4/31
64.3% Z 9/14
40.9% Z 9/22
78.3% Z 18/23
8.6% Z 3/35
40% Z 4/10
Responders (GO) presented
with a higher frequency of
concomitant CCB use when
compared to nonresponders
osporin-A; GEZ gingival enlargement; GOZ gingival overgrowth;
of gingival overgrowth; NIF Z nifedipine; Tcr Z tacrolimus;
reports of gingival overgrowth in patients receiving Tcr with and
ally significant overgrowth (Thomason et al, 1993).33
ndimu et al, 1993, 2001).34,35
34 S.-Y. Chen et altreated with drugs when compared with the animals in the
control group. Significantly increased gingival dimensions
were noted consistently in the animals of the tacrolimus
group when compared with the control animals, which
indicated that gingival overgrowth could be induced by
tacrolimus in this animal model, although to a lesser extent
than that induced by nifedipine. Moreover, concomitant
treatment of nifedipine did not aggravate tacrolimus-
induced gingival overgrowth because the morphology in
the combined-drug group was either similar to that in the
tacrolimus group or not greater than that in the nifedipine
group (Fig. 2BeE). A histological analysis showed similar
findings, regardless of the tissue level examined (Fig. 4).
In this study, the gingival probing depth and the kerati-
nized gingival width on the buccal surface of the first molar
were also measured to evaluate the dimensions of gingival
overgrowth on the posterior teeth. However, these two
methods have limitations. Gingival probing depth was
added as one of the methods to evaluate gingival over-
growth as it has been used in a previous study.22 Despite the
widespread use of the periodontal probe as a tool for the
measurement of pocket depth, a certain degree of error
exists in the technique of measuring the root surface at the
level of the greatest penetration of the probe tip. List-
garten et al23 suggested that the tip of the periodontal
probe would be located at the demarcation line between
the junction epithelium and the site of connective tissue
attachment, and possibly within the connective tissue.
Moreover, the recorded depth can be influenced by many
other factors (including force, angulation, and tissue
inflammation). By contrast, the width of the keratinized
gingiva may represent the true gingival overgrowth, as it is
presented in the gingiva and not in the mucosa. However,
the widths may vary at different sites, which make it
difficult to compare the minor changes of overgrowth.
During microscopic evaluation, our histological mea-
surements involved a two-dimensional measurement,
including measurements of the tissue buccolingual thick-
ness and tissue mesiodistal width, in the incisal papilla;
however, three-dimensional results could still be inferred
from the two-dimensional data because they were taken at
two different tissue levels recording. Similar findings of
significantly increased total and connective tissue areas of
central papilla were observed in all drug groups when
compared to that in the control group, and the greatest
total and connective tissue areas were observed in the
nifedipine group. However, the epithelial tissue areas were
similar among the treatment groups, regardless of whether
they are at levels 1 or 2. These findings imply that the
connective tissue may be the target tissue for the gingival
overgrowth induced by nifedipine or tacrolimus. Under a
different mechanism with respect to cyclosporin A, both
the epithelial cells and the stroma cells are the target cells
during the development of gingival overgrowth. 15,24,25
Cyclosporin A and tacrolimus, which have similar phar-
macodynamics, have been selected and used successfully
for organ transplantation and autoimmune diseases.1,26
Studies have suggested a replacement of cyclosporin A by
tacrolimus4e8,27,28 due to much less severity in gingival
overgrowth.4,5 A concomitant prescription of nifedipine
may attenuate tacrolimus-induced side effects.4 Although
the exact effect of the two concomitant drugs is uncertain,calcium channel blockers may be a significant risk factor
for the tacrolimus-induced gingival overgrowth.4,5,11
Table 12,4,5,8,11,12,31,32 summarizes the clinical studies
related to the development of gingival overgrowth in pa-
tients receiving tacrolimus with and without calcium
channel blockers. In the present study, however, our results
questioned the synergic effect of the concomitant use of
nifedipine and tacrolimus on the overgrowth. Although the
exact reason is still unknown, the treatment duration,
dosage of drugs, conditions of oral hygiene, or even animal
model tested might have a certain impact on the results
obtained. For instance, the overgrown gingiva was shown to
be ambiguous in short-term tacrolimus administration,
whereas obvious changes occurred in rats after a long-term
drug administration (for 240 days).29 In the present study,
overgrown gingiva was recorded in the animals receiving
tacrolimus, but to a much less extent than in those receiving
nifedipine (Fig. 2e4). Results also indicated that the present
animal model is sensitive to develop gingival overgrowth
after administration of both tacrolimus and nifedipine.30
Nevertheless, further detailed studies are still needed.
In conclusion, the macro- and microscopic changes of
mandibular central papillary morphology and gingival
measurements around the first mandibular molars,
including the gingival width and probing depth, all showed
that gingival overgrowth could be induced in animals
receiving tacrolimus, although to a less extent than in those
receiving nifedipine. Moreover, the concomitant adminis-
tration of nifedipine with tacrolimus did not aggravate the
gingival overgrowth induced by a single drug (either
nifedipine or tacrolimus).Conflicts of interest
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